Zhou Lu-Qiu, Ma Zhen, Shi Xiao-Feng, Yin Xi-Long, Huang Kai-Xiong, Jiu Zhi-Song, Kong Wei-Long
1Department of Neurosurgery, 2Department of Respiratory Diseases, Shenzhen Longgang Central Hospital, Shenzhen, China.
Asian Pac J Cancer Prev. 2011;12(10):2547-50.
This study aimed to examine associations between polymorphisms in the X-ray cross- complementing group 1 (XRCC 1) gene and risk of glioma in a Chinese population.
We performed a hospital-based case-control study with 271 cases and 289 controls in Guangdong province, China. Cases were patients newly diagnosed with pathologically confirmed glioma in two hospitals between June 2006 and May 2010. Controls were hospitalized individuals without cancer, frequency matched by sex and age. Three SNPs in XRCC1 gene, Arg399Gln (rs25487), Arg194Trp (rs1799782) and Arg280His (rs25489), were analyzed by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) based method. Unconditional logistic regression was used to estimate the odds ratios (ORs) of polymorphisms in XRCC1 gene for glioma.
The Arg399Gln polymorphism was significantly associated with risk of glioma. Individuals with the Gln/Gln genotype had a significantly increased likelihood of developing glioma compared with those with the Arg/Arg genotype (adjusted OR = 1.93, 95% CI: 1.04 - 3.58), especially among males and individuals aged 50 years or older.
The XRCC1 Arg399Gln polymorphism may be a useful susceptibility biomarker for glioma. Further studies in Chinese populations with larger sample sizes are now warranted.
本研究旨在探讨中国人群中X射线交叉互补基因1(XRCC 1)基因多态性与胶质瘤风险之间的关联。
我们在中国广东省进行了一项基于医院的病例对照研究,共纳入271例病例和289例对照。病例为2006年6月至2010年5月期间在两家医院新诊断为病理确诊胶质瘤的患者。对照为无癌症的住院个体,按性别和年龄进行频率匹配。采用基于聚合酶链反应-限制性片段长度多态性(PCR-RFLP)的方法分析XRCC1基因中的三个单核苷酸多态性(SNP),即Arg399Gln(rs25487)、Arg194Trp(rs1799782)和Arg280His(rs25489)。采用非条件逻辑回归估计XRCC1基因多态性与胶质瘤的比值比(OR)。
Arg399Gln多态性与胶质瘤风险显著相关。与Arg/Arg基因型个体相比,Gln/Gln基因型个体患胶质瘤的可能性显著增加(校正OR = 1.93,95%CI:1.04 - 3.58),尤其是在男性和50岁及以上个体中。
XRCC1 Arg399Gln多态性可能是胶质瘤有用的易感性生物标志物。现在有必要对更大样本量的中国人群进行进一步研究。